PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.72%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
-21.99%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
32.68%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
32.51%
EPS growth of 32.51% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
32.51%
Diluted EPS growth of 32.51% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-20.05%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-102666.73%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-29000.87%
Negative 5Y OCF/share CAGR while CRVO is at 94.81%. Joel Greenblatt would question the firm’s operational model or cost structure.
0.57%
3Y OCF/share CAGR under 50% of CRVO's 86.38%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-765363.95%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-27613.67%
Negative 5Y net income/share CAGR while CRVO is 97.67%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-208.91%
Negative 3Y CAGR while CRVO is 97.74%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
82516.86%
Equity/share CAGR of 82516.86% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5226.69%
5Y equity/share CAGR above 1.5x CRVO's 114.71%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1660.30%
3Y equity/share CAGR above 1.5x CRVO's 100.76%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Negative asset growth while CRVO invests at 906.37%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.72%
We have a declining book value while CRVO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-32.96%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
44.99%
R&D dropping or stable vs. CRVO's 377.32%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.08%
We cut SG&A while CRVO invests at 47.81%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.